ImageneBio (IMA) Free Cash Flow (2020 - 2025)
ImageneBio's (IMA) quarterly Free Cash Flow came in at -$21.5 million in Q3 2025, down 265.83% year-over-year from $13.0 million in Q3 2024, and down 80.62% quarter-over-quarter from -$11.9 million in Q2 2025.
Powered by 
Analysis
ImageneBio (IMA) Free Cash Flow (2020 - 2025) Analysis & Trends
ImageneBio has disclosed Free Cash Flow across 6 years of filings, most recently posting -$21.5 million for Q3 2025.
- In Q3 2025, Free Cash Flow fell 265.83% year-over-year to -$21.5 million; the TTM figure through Sep 2025 stood at -$68.8 million (down 72.29% YoY), while the FY2024 annual figure was -$46.0 million, up 42.61% from the prior year.
- Free Cash Flow came in at -$21.5 million for Q3 2025 at ImageneBio, down from -$11.9 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $13.0 million in Q3 2024 to a low of -$28.2 million in Q4 2024.
- Average Free Cash Flow over 5 years is -$16.0 million, with a median of -$18.1 million recorded in 2023.
- Year-over-year, Free Cash Flow jumped 164.82% in 2024 and plunged 265.83% in 2025.
- Over 5 years, Free Cash Flow stood at -$13.9 million in 2021, then slipped by 28.51% to -$17.9 million in 2022, then dropped by 23.45% to -$22.1 million in 2023, then dropped by 27.53% to -$28.2 million in 2024, then rose by 23.67% to -$21.5 million in 2025.
- Per Business Quant data, the three most recent Free Cash Flow figures were -$21.5 million in Q3 2025, -$11.9 million in Q2 2025, and -$7.2 million in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 3.49 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 3.43 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 1.01 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 572.80 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -563.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 292.04 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 408.00 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -268.64 Mn |
| 10 | ImageneBio | 42.89 Mn | -92.46 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | -21.50 Mn |
| Jun 30, 2025 | -11.90 Mn |
| Mar 31, 2025 | -7.23 Mn |
| Dec 31, 2024 | -28.16 Mn |
| Sep 30, 2024 | 12.96 Mn |
| Jun 30, 2024 | -12.50 Mn |
| Mar 31, 2024 | -18.30 Mn |
| Dec 31, 2023 | -22.08 Mn |
| Sep 30, 2023 | -20.00 Mn |
| Jun 30, 2023 | -18.14 Mn |
| Mar 31, 2023 | -19.94 Mn |
| Dec 31, 2022 | -17.89 Mn |
| Sep 30, 2022 | -17.48 Mn |
| Jun 30, 2022 | -20.36 Mn |
| Mar 31, 2022 | -19.82 Mn |
| Dec 31, 2021 | -13.92 Mn |
| Sep 30, 2021 | -18.17 Mn |
| Jun 30, 2021 | -15.91 Mn |
| Mar 31, 2021 | -14.01 Mn |
| Dec 31, 2020 | -13.21 Mn |